NCT01667679View on ClinicalTrials.gov

Efficacy and Safety of 20 mg Sumatriptan Powder Delivered Intranasally With the Bi-directional Device Compared With 100 mg Sumatriptan Tablets in Adults With Acute Migraine With or Without Aura

PHASE3CompletedINTERVENTIONAL
Enrollment

275

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

March 31, 2014

Study Completion Date

June 30, 2014

Conditions
MigraineHeadaches
Interventions
DRUG

100 mg Sumatriptan Tablet and OPTINOSE Placebo delivered nasally

DRUG

OPTINOSE SUMATRIPTAN delivered nasally and placebo tablet

Trial Locations (13)

14226

DENT Neurologic Institute, Amherst

19107

Jefferson Headache Center, Philadelphia

27103

PMG Research of Winston Salem, LLC, Winston-Salem

27405

Headache Welness Center, Greensboro

29464

Coastal Carolina Research Center, Mt. Pleasant

33407

Premiere Research Institute, West Palm Beach

63141

Mercy Health Research, St Louis

65807

ClinVest, Springfield

90404

California Medical Clinic for Headache, Santa Monica

94109

San Francisco Clinical Research Center, San Francisco

06824

Associated Neurologists of Southern CT, P.C., Fairfied

02472

MedVadis, Watertown

48104-5199

Michigan Head and Pain Institute, Ann Arbor

Sponsors
All Listed Sponsors
lead

Avanir Pharmaceuticals

INDUSTRY

NCT01667679 - Efficacy and Safety of 20 mg Sumatriptan Powder Delivered Intranasally With the Bi-directional Device Compared With 100 mg Sumatriptan Tablets in Adults With Acute Migraine With or Without Aura | Biotech Hunter | Biotech Hunter